Pharmaceuticals & Therapeutics

A key deal locking in generic drug prices is extended, promising billions in savings for healthcare and providing crucial stability for a fragile industry.

New research shows play instantly bonds families. For confectioner Kinder, it's also a savvy move to capture the lucrative family wellness market.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

The maker of Crisco and Cream of Wheat extends its debt maturity to 2031, but at a staggering 11% rate, revealing the harsh realities of today's credit markets.

Athletes are ditching complex supplement stacks for all-in-one EAA formulas. We explore the science and the industry shift fueling this minimalist movement.

Polish biotech firm Urteste S.A. enrolls its first patient in a pivotal trial for a non-invasive pancreatic cancer test, a milestone in the global race for early diagnosis.

Cytovance Biologics' new cell line service boasts top-tier yields. This strategic shift toward a 'one-stop-shop' model could redefine speed and cost in biopharma.

Soaring healthcare costs, fueled by GLP-1 drugs, have employers trapped. A new report shows why flexible benefits are becoming a critical survival strategy.

An expanded partnership between GENESIS Pharma and Alnylam is set to bring revolutionary RNAi therapies to the Nordics. But can it navigate the region's tough economic hurdles?

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

New clinical data suggests Cullinan Therapeutics' cancer-fighting tech could offer durable, treatment-free remission for severe RA and lupus patients.

With $101M from top VCs, Ethyreal Bio emerges from stealth to target the root cause of both Graves' Disease and Thyroid Eye Disease with a single antibody.

A landmark deal sees Novartis invest up to $1.4B in Orionis Biosciences' AI platform, aiming to turn the chance discovery of 'molecular glue' drugs into a science.

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

As manufacturers face immense pressure to cut supply chain emissions, one company's blend of solar power and closed-loop recycling offers a tangible blueprint.

As Europe grapples with energy costs and net-zero goals, Cortec's Croatian subsidiaries offer a powerful model for a circular, self-powered supply chain.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

Biotech firm Sensorion drops one gene therapy to fast-track another, aiming to cure GJB2-related hearing loss, the leading cause of genetic deafness.

A popular wellness gummy is at the center of a scam epidemic. But is the product the problem, or a vast network of digital counterfeiters? We investigate.